{"id":"W2979691426","doi":"10.1182/blood.v108.11.3556.3556","title":"Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.","year":2006,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":6,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Lenalidomide; Medicine; Multiple myeloma; Dexamethasone; Internal medicine; Thalidomide; Interim analysis; Data monitoring committee; Expanded access; Neutropenia; Refractory (planetary science); Oncology; Surgery; Clinical trial; Toxicity","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009473072,0.0002466487,0.0003690307,0.0002810634,0.0004939177,0.0003344915,0.0003499405,0.0003875738,0.005132813],"category_scores_gemma":[0.0006917409,0.0001928846,0.0001837597,0.0003282327,0.0002539631,0.0002718675,0.0003619634,0.000519783,0.001073586],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008069368,"about_ca_system_score_gemma":0.001275707,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.004350603,"about_ca_topic_score_gemma":0.01108504,"domain_scores_codex":[0.9996766,0.0001079601,0.0000218472,0.00007405614,0.00006758513,0.00005198955],"domain_scores_gemma":[0.9995397,0.00007053629,0.00009838404,0.00002204156,0.00005091937,0.0002183603],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.1273489,0.0210536,0.3384056,0.0009284359,0.0004484926,0.001691171,0.0006044134,0.000347899,0.03287533,0.0003013018,0.02174819,0.4542466],"study_design_scores_gemma":[0.0407785,0.08635738,0.823983,0.0002213769,0.0005281631,0.002106548,0.0002552644,0.0009485679,0.005458926,0.0001782437,0.03914398,0.00003997614],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.984832,0.003574786,0.00052799,0.0005240663,0.00005832087,0.003230302,0.002078268,0.0001751709,0.004999026],"genre_scores_gemma":[0.986587,0.001259537,0.001886934,0.001163398,0.0001613407,0.001516158,0.002009803,0.00001759132,0.005398162],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005132813,"threshold_uncertainty_score":0.01717103,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04386297423507086,"score_gpt":0.342573809831714,"score_spread":0.2987108355966431,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}